Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Evinacumab-dgnb (Evkeeza)

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

EVKEEZA (evinacumab-dgnb) injection (opens in a new tab)Original source URL: https://globalrph.com/dilution/evkeeza-evinacumab-dgnb-injection/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/evkeeza-evinacumab-dgnb-injection/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:46:47.206787+00:00
Source location
div.post-content
Packaged content SHA-256
b164584d3ece0668a8ae70515a36d701072fa3ed9136b45677e1a81fff18c719
Original response SHA-256
3839b75e12425ffcf07c2aefc2cee9a6bbe15f734d3eebf6d1037453bef3f0e2
Source body SHA-256
87369ca312675c71ef190301ba2c3642e0d7f1cf30ee73cb0ef7c1a44fca1197

EVKEEZA™ (evinacumab-dgnb) injection

PRESCRIBING HIGHLIGHTS: Please see package insert for additional information and possible updates to ensure safe and effective use of this medication. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. Please read the disclaimer carefully BEFORE accessing or using this site. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Drug UPDATES: [Drug information]
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)

Usual Diluents Return to article top

NS, D5W

Standard Dilutions [Amt of drug] [Infusion vol] [Infusion rate] Return to article top

[15 mg/kg ] [250 ml ] [60 minutes*]

Must use an add-on or inline filter during administration (see below).

The final concentration of the diluted solution should be between 0.5 mg/mL and 20 mg/mL depending on the patient's current body weight. Administer EVKEEZA diluted solution via IV infusion over 60 minutes through an IV line containing a sterile, in-line or add-on, 0.2-micron to 5-micron filter.

*The rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of adverse reactions, including infusion or hypersensitivity reactions

.
  • The recommended dose of EVKEEZA is 15 mg/kg administered by intravenous (IV) infusion over 60 minutes once monthly (every 4 weeks).
  • Calculate the dose (mg), total volume (mL) of EVKEEZA required, and the number of vials required based on the patient's current body weight.
  • Visually inspect the solution for cloudiness, discoloration, and particulate matter prior to administration. EVKEEZA is a clear to slightly opalescent, colorless to pale-yellow solution. Do not administer if the solution is cloudy or discolored or contains particulate matter.
  • EVKEEZA vials are single-dose containers and do not contain a preservative. Observe aseptic technique when preparing EVKEEZA.
  • Do not shake the vial. Withdraw the required volume from the vial(s) of EVKEEZA and transfer into an IV infusion bag containing a maximum volume of 250 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Mix the diluted solution by gentle inversion; do not shake.
  • Administer the diluted solution immediately after preparation and discard any unused portion left in the vial.
  • If not used immediately, store the diluted solution refrigerated at 2 °C to 8 °C (36 °F to 46 °F) for no more than 24 hours from the time of preparation OR at room temperature up to 25 °C (77 °F) for no more than 6 hours from the time of infusion preparation to the end of the infusion. Do not freeze the diluted solution.

Description:
Evinacumab-dgnb is an angiopoietin-like protein 3 (ANGPTL3) inhibitor monoclonal antibody (IgG4 isotype) produced by recombinant DNA technology in Chinese hamster ovary (CHO) cell suspension culture. Evinacumab-dgnb has an approximate molecular weight of 146 kDa.

EVKEEZA (evinacumab-dgnb) injection is a sterile, preservative-free solution for intravenous use. The solution is clear to slightly opalescent, colorless to pale-yellow, and free from visible particles.

Each vial contains 345 mg/2.3 mL or 1,200 mg/8 mL. Each mL contains 150 mg of evinacumab-dgnb, and L-arginine hydrochloride (14.8 mg), L-histidine (0.74 mg), L-histidine monohydrochloride monohydrate (1.1 mg), L-proline (30 mg), polysorbate 80 (1 mg) and Water for Injection, USP. The pH is 6.

CLINICAL PHARMACOLOGY: Return to article top

Mechanism of Action:

Evinacumab-dgnb is a recombinant human monoclonal antibody that binds to and inhibits ANGPTL3. ANGPTL3 is a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). Evinacumab-dgnb inhibition of ANGPTL3 leads to reduction in LDL-C, HDL-C, and triglycerides (TG). Evinacumab-dgnb reduces LDL-C independent of the presence of LDL receptor (LDLR) by promoting very low-density lipoprotein (VLDL) processing and clearance upstream of LDL formation. Evinacumab-dgnb blockade of ANGPTL3 lowers TG and HDL-C by rescuing LPL and EL activities, respectively.

INDICATIONS AND USAGE Return to article top

INDICATIONS AND USAGE:

EVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).

Limitations of Use:

  • The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
  • The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.

CONTRAINDICATIONS Return to article top

Contraindications:

EVKEEZA is contraindicated in patients with a history of serious hypersensitivity reaction to evinacumab-dgnb or to any of the excipients in EVKEEZA. Serious hypersensitivity reactions, including anaphylaxis, have occurred.

WARNINGS AND PRECAUTIONS:

5.1 Serious Hypersensitivity Reactions

Serious hypersensitivity reactions have occurred with EVKEEZA. In clinical trials, 1 (1%) EVKEEZA-treated patient experienced anaphylaxis versus 0 (0%) patients who received placebo. If signs or symptoms of serious hypersensitivity reactions occur, discontinue EVKEEZA infusion, treat according to the standard-of-care, and monitor until signs and symptoms resolve. EVKEEZA is contraindicated in patients with a history of serious hypersensitivity reaction to evinacumab-dgnb [see CONTRAINDICATIONS].

5.2 Embryo-Fetal Toxicity

Based on the findings in animal reproduction studies, EVKEEZA may cause fetal harm when administered to pregnant patients. Administration of evinacumab to rabbits during organogenesis caused increases in fetal malformations at doses below the human exposure. Advise patients who may become pregnant of the risk to a fetus. Consider obtaining a pregnancy test prior to initiating treatment with EVKEEZA. Advise patients who may become pregnant to use effective contraception during treatment with EVKEEZA and for at least 5 months following the last dose of EVKEEZA

ADVERSE REACTIONS Return to article top

ADVERSE REACTIONS:

Common adverse reactions (≥ 5%) were nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, and nausea. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Regeneron at 1-833-385-3392 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug information

DOSAGE AND ADMINISTRATION Return to article top

DOSAGE AND ADMINISTRATION:

2.1 Recommended Dosage

  • The recommended dose of EVKEEZA is 15 mg/kg administered by intravenous (IV) infusion over 60 minutes once monthly (every 4 weeks).
  • If a dose of EVKEEZA is missed, administer as soon as possible. Thereafter, EVKEEZA should be scheduled monthly from the date of the last dose.
  • Assess LDL-C when clinically appropriate. The LDL-lowering effect of EVKEEZA may be measured as early as 2 weeks after initiation.

2.2 Preparation Instructions for Intravenous Infusion

  • Calculate the dose (mg), total volume (mL) of EVKEEZA required, and the number of vials required based on the patient's current body weight.
  • Visually inspect the solution for cloudiness, discoloration, and particulate matter prior to administration. EVKEEZA is a clear to slightly opalescent, colorless to pale-yellow solution. Do not administer if the solution is cloudy or discolored or contains particulate matter.
  • EVKEEZA vials are single-dose containers and do not contain a preservative. Observe aseptic technique when preparing EVKEEZA.
  • Do not shake the vial. Withdraw the required volume from the vial(s) of EVKEEZA and transfer into an IV infusion bag containing a maximum volume of 250 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Mix the diluted solution by gentle inversion; do not shake.
  • The final concentration of the diluted solution should be between 0.5 mg/mL and 20 mg/mL depending on the patient's current body weight.
  • Administer the diluted solution immediately after preparation and discard any unused portion left in the vial.
  • If not used immediately, store the diluted solution refrigerated at 2 °C to 8 °C (36 °F to 46 °F) for no more than 24 hours from the time of preparation OR at room temperature up to 25 °C (77 °F) for no more than 6 hours from the time of infusion preparation to the end of the infusion. Do not freeze the diluted solution.

2.3 Administration Instructions for Intravenous Infusion

  • If refrigerated, allow the diluted solution to come to room temperature prior to administration.
  • Administer EVKEEZA diluted solution via IV infusion over 60 minutes through an IV line containing a sterile, in-line or add-on, 0.2-micron to 5-micron filter.
  • Do not mix other medications with EVKEEZA or administer other medications concomitantly via the same infusion line.
  • The rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of adverse reactions, including infusion or hypersensitivity reactions [see WARNINGS AND PRECAUTIONS (5.1) and ADVERSE REACTIONS (6.1)].
  • EVKEEZA can be administered without regard to the timing of lipoprotein apheresis.
DOSAGE FORMS AND STRENGTHS:

Injection: 345 mg/2.3 mL (150 mg/mL) and 1,200 mg/8 mL (150 mg/mL) solution in single-dose vials.

Storage and Stability Return to article top

EVKEEZA (evinacumab-dgnb) injection is a clear to slightly opalescent, colorless to pale yellow solution. It is supplied as one single-dose vial per carton.

  • 345 mg/2.3 mL (150 mg/mL) NDC 61755-013-01
  • 1,200 mg/8 mL (150 mg/mL) NDC 61755-010-01

Storage

Store in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Store the vial in the original carton to protect from light. Do not freeze. Do not shake.

EVKEEZA does not contain a preservative. If not used immediately, store the diluted solution refrigerated at 2 °C to 8 °C (36 °F to 46 °F) for no more than 24 hours from the time of preparation OR at room temperature up to 25 °C (77 °F) for no more than 6 hours from the time of infusion preparation to the end of the infusion

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      evinacumab-dgnb-evkeeza
      Source IDH51-2EE01C5AB9C2C1EE43D83D4F
      Generic name
      Evinacumab-dgnb (Evkeeza)
      Source IDH51-A8FDE770B5C296740537AD30
      Class
      Biologics and immunotherapy
      Source IDH51-A8ECC6FA82D48BD47DB0E29D
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-B46B672726F1841296052F43
      Primary uses
      1. The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic.
        Source IDH51-0987498FBDE5401236DB5422
      Mechanism
      Inhibits ANGPTL3, increasing lipase activity and lowering atherogenic lipoproteins independently of the LDL receptor.
      Source IDH51-692F1105658DD7B7B604420B
      Mechanism level
      drug_specific
      Source IDH51-53DBE7894683CF2F8DD3698F
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-0253308F382286C396FE2B63
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-71B745686BD46236DE039E26
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-323902BA86DAC748181F9C46
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-FC03A7D379F7EB50D3953221
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-5404814743B7B927F1F4939F
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-6F9A3370EBA54BDF1E352598
      Legacy title
      Evinacumab-dgnb (Evkeeza)
      Source IDH51-4AF7FA8FB53EB9EAE2C1D7AE
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-A2A17407B44895ED5AEFCB21
      Search text
      Evinacumab-dgnb (Evkeeza) Biologics and immunotherapy Legacy GlobalRPh directory entry The current labeled immune, hematologic, neurologic, metabolic, or inflammatory indication for this targeted biologic. Inhibits ANGPTL3, increasing lipase activity and lowering atherogenic lipoproteins independently of the LDL receptor. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-595BCA0B9D3FAE1B7B101099
      Official access mode
      none
      Source IDH51-C28B4D3217F22DBCC1558071
      Official access reason
      No source-backed DailyMed action has been verified for this umbrella or legacy record; identify the exact product before searching.
      Source IDH51-9E07B2C9A180B47A2FA15AF1

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-6C1FF40F6C90806719678D69
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-81CD4E5E2EA669D772B30BE7
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-9869F79DFC8695E1C6A38902

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-541E8D5BF60C6D88974E48B7

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-B2A923D9FF452AA6781A3F10
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      evinacumab-dgnb-evkeeza
      Source IDH51-B5B65F4E31E70C6708D7F6EA
      Legacy title
      Evinacumab-dgnb (Evkeeza)
      Source IDH51-079E9397779C0DB60301B0D0
      Generic name
      Evinacumab-dgnb (Evkeeza)
      Source IDH51-2B68D81D18EB55D170D43574
      Class
      Biologics and immunotherapy
      Source IDH51-2E4E31F9677A6A14D26F6D4B
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-A8306CE8BF6D4793BCD48C71
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-51E73A3AB527750C302247C0
      Populations
      1. Population not yet normalized
        Source IDH51-7F74B16D6DE9E8077C9D80E6
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-A78299C6ECF34AD6E6C680E2
      High alert
      false
      Source IDH51-D33757A5A3C17579425B06C4
      Hazardous
      false
      Source IDH51-7AF377795B51B5247A28D26E
      Status
      Legacy migration
      Source IDH51-C5973773ED063D90715AE1BC
      Version added
      Legacy
      Source IDH51-CA736907D848FBC265C46695
      Sources
      LabelUrlKind
      Source IDH51-A14E8BC46207C17ACC835577
      GlobalRPh legacy IV dilution monograph
      Source IDH51-0B820F1E1CA3B0B781AFE6ED
      legacy:auto
      Source IDH51-7B17B819BE3BB8F8B0A5E3B6
      Legacy
      Source IDH51-F43DB31F20D621D1E0D72718
      Clinical release verification
      Audit version
      3.4
      Source IDH51-4517CF072E2B5C38C8AB7747
      Audited on
      2026-08-30
      Source IDH51-E5433FFCE5B66CDC538AB6E9
      Level
      red
      Source IDH51-54CA63AF565C9A6A4A499D43
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-C4105E80EA7CAC8EA684DF41
      Exact current label candidate
      false
      Source IDH51-7730F42C143B4FD212FFFFF8
      Reference url count
      0
      Source IDH51-3187FFE59FE1C76FDE140FE9
      Broken reference count
      0
      Source IDH51-211168E136C046124BA977A4
      Point of use confirmation required
      true
      Source IDH51-F394011D776BB0303DD799FB
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-B97E30CAE583BB361DE9D83D

      Dosing source fields

      Id
      evinacumab-dgnb-evkeeza
      Source IDH51-D192076E99B68CD081285F96
      Generic name
      Evinacumab-dgnb (Evkeeza)
      Source IDH51-478B3ADCAEA9DD2770AC5000
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-C2B4754741056D8F2B6F2522
      Package insert
      Query name
      Evinacumab-dgnb
      Source IDH51-A51B6064850D3581898D7B44
      Product and route must match
      true
      Source IDH51-8B7564BF3E4DBC5CD482397B
      Live current label enabled
      false
      Source IDH51-37D4AEE708983DD57AD53C9F
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-A9CC51739FAD6810AB9138D1
      Direct official label access enabled
      true
      Source IDH51-E3C5237ECA1C06BE4C93BF82
      Outbound server request required
      false
      Source IDH51-9A335BFA2E4D030E8B3E6252
      Local summary status
      not_bundled
      Source IDH51-4351EEE57EFB9753630E3A02
      Clinical review
      Locally normalized
      false
      Source IDH51-B2C2B64467BC1B1C4D8DC40E
      Reviewed
      2026-08-29
      Source IDH51-6801710F762D82ADD41A10A7
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-A6F30A2A54E817CA9916DAA0
      Clinical release verification
      Audit version
      3.4
      Source IDH51-C5B46CD3D35E29A371382525
      Audited on
      2026-08-30
      Source IDH51-571E0F58A1B1DCAF422F5A51
      Level
      red
      Source IDH51-7BD664A93B8103D1F6F83BF2
      Release gate
      unverified_or_unclassified_sources_do_not_release_as_current
      Source IDH51-0229CA8301DB71BEC3630A8C
      Exact current label candidate
      false
      Source IDH51-8306B9FEBE353863B328C8D9
      Reference url count
      0
      Source IDH51-FCB7B812A32E18CD1A328EFC
      Broken reference count
      0
      Source IDH51-804FF51CEB5F6124594861E9
      Point of use confirmation required
      true
      Source IDH51-8B574E701394E53585967DA1
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-249F87A34A0A6AC1DC88865D
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      evinacumab-dgnb-evkeeza
      Source IDH51-6512C0144389C4F6D9108768
      Name
      Evinacumab-dgnb (Evkeeza)
      Source IDH51-0D081706FBBC50033071F167
      Therapeutic class
      Biologics and immunotherapy
      Source IDH51-0F449E24AD1EF295BA9F2FDA
      Review version
      3.1
      Source IDH51-CC630AFDC7A02A3643CFE227
      Review date
      2026-08-30
      Source IDH51-55707D91E279A1E339CA5FFB
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-4627CD86BCEAE61498942073
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-5F57E16FAD06563D8272A62C
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-8F1A3572EBB3C29ECE7F2FCC
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-DA97BEA7BDB95140A64B221E
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-CC15FDE770FC8FC7777A0F60
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-5C3233EAB9BBD02F5F83AC8E
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-CE63F44A3787F051C2853146
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-410C90D52F03739A18C16270
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-4A607EB7E55E34E16FB2456C
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-8C93630E0B898D637A174D32
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-4AD3517C6616FE7CCF6CCCB5
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-35C380BEE6AA48542216229F
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-EAF4D13547B1F5D188725D62
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-69F72AB4BAB5F4CE43E06719
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-F8DEE6FCC2D7E5F7432572CE
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-296824FB8260CEF047CB8369
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-D4D80E7FC3EA07E83F2A8210
      Adult dosing range
      Primary
      not_found
      Source IDH51-316D95A65776FB7BB36C5335
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-42664667A20B5C3E96DDDA2F
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-189D47E44776C97A8EB04983
      Infusion time
      Primary
      not_found
      Source IDH51-45864F6CF1D82BC60A8773BE
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-5E38010A48A5092C2BFCA6BC
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-D97222512202E5DEB7A06999
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-B8C1358511929BBD2571D090
      Guide generation allowed
      false
      Source IDH51-141C774CE4832650DB103952
      Pediatric
      Applicability
      not_established
      Source IDH51-BC91E747BB2AFB58A5A8716A
      Guide generation allowed
      false
      Source IDH51-0DD4FBDD8FF54BDDBA206A48
      Neonatal
      Applicability
      not_established
      Source IDH51-DE1609F48512C4F41D70BBAB
      Guide generation allowed
      false
      Source IDH51-B9A55F89EC082ECFF3B705E3
      Route presence
      Structured dilution
      false
      Source IDH51-7B0C84B3938F20F973BF7FD5
      Iv push
      false
      Source IDH51-7B18B643CEF355A7AAF9BA6C
      Continuous infusion
      false
      Source IDH51-BDF6BFAC5A9100E11B8638CC
      Pediatric source
      false
      Source IDH51-B1E63EC8D2582985534461DF
      Neonatal source
      false
      Source IDH51-54377031C196427143ECE250
      Legacy reference
      Status
      not_available
      Source IDH51-94C78715ABEC269AD708612E
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-5656B036F86F26351572E935
      Source files
      1. catalog.json
        Source IDH51-58FF25B98DE8B2211DF8833F
      2. dosing.json
        Source IDH51-9A11481617C2C708F1E780BC
      3. legacy-map.json
        Source IDH51-4A79D7F8F00FF3060AE1E7DE
      4. review-queue.json
        Source IDH51-CA059C8203FD7A5C1559C666
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-AD9788269316D8B0947B2D54
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-B5B65F4E31E70C6708D7F6EAcatalog.json
      /records/99/id
      Historical; current review incomplete
      H51-079E9397779C0DB60301B0D0catalog.json
      /records/99/legacy_title
      Historical; current review incomplete
      H51-2B68D81D18EB55D170D43574catalog.json
      /records/99/generic_name
      Historical; current review incomplete
      H51-2E4E31F9677A6A14D26F6D4Bcatalog.json
      /records/99/class
      Historical; current review incomplete
      H51-A8306CE8BF6D4793BCD48C71catalog.json
      /records/99/subclass
      Historical; current review incomplete
      H51-51E73A3AB527750C302247C0catalog.json
      /records/99/summary
      Historical; current review incomplete
      H51-541E8D5BF60C6D88974E48B7catalog.json
      /records/99/warnings/0
      Historical; current review incomplete
      H51-B2A923D9FF452AA6781A3F10catalog.json
      /records/99/stability_notes/0
      Historical; current review incomplete
      H51-7F74B16D6DE9E8077C9D80E6catalog.json
      /records/99/populations/0
      Historical; current review incomplete
      H51-A78299C6ECF34AD6E6C680E2catalog.json
      /records/99/evidence_tier
      Historical; current review incomplete
      H51-D33757A5A3C17579425B06C4catalog.json
      /records/99/high_alert
      Historical; current review incomplete
      H51-7AF377795B51B5247A28D26Ecatalog.json
      /records/99/hazardous
      Historical; current review incomplete
      H51-C5973773ED063D90715AE1BCcatalog.json
      /records/99/status
      Historical; current review incomplete
      H51-3A46E9427DE50662717518F9catalog.json
      /records/99/reviewed
      Historical; current review incomplete
      H51-CA736907D848FBC265C46695catalog.json
      /records/99/version_added
      Historical; current review incomplete
      H51-A14E8BC46207C17ACC835577catalog.json
      /records/99/sources/0
      Historical; current review incomplete
      H51-0B820F1E1CA3B0B781AFE6EDcatalog.json
      /records/99/sources/0/label
      Historical; current review incomplete
      H51-7B17B819BE3BB8F8B0A5E3B6catalog.json
      /records/99/sources/0/url
      Historical; current review incomplete
      H51-F43DB31F20D621D1E0D72718catalog.json
      /records/99/sources/0/kind
      Historical; current review incomplete
      H51-4517CF072E2B5C38C8AB7747catalog.json
      /records/99/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-E5433FFCE5B66CDC538AB6E9catalog.json
      /records/99/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-54CA63AF565C9A6A4A499D43catalog.json
      /records/99/clinical_release_verification/level
      Historical; current review incomplete
      H51-C4105E80EA7CAC8EA684DF41catalog.json
      /records/99/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-7730F42C143B4FD212FFFFF8catalog.json
      /records/99/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-DD8C33DA20BB10705A6B7338catalog.json
      /records/99/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-7982FD07B00944F170336DAAcatalog.json
      /records/99/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-9F006F89C8B1E3ECE09A82C1catalog.json
      /records/99/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-3187FFE59FE1C76FDE140FE9catalog.json
      /records/99/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-211168E136C046124BA977A4catalog.json
      /records/99/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-F394011D776BB0303DD799FBcatalog.json
      /records/99/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-B97E30CAE583BB361DE9D83Dcatalog.json
      /records/99/clinical_release_verification/note
      Historical; current review incomplete
      H51-0038ECB1D76ED061831B3FBAcatalog.json
      /records/99/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-D192076E99B68CD081285F96dosing.json
      /records/99/id
      Historical; current review incomplete
      H51-478B3ADCAEA9DD2770AC5000dosing.json
      /records/99/generic_name
      Historical; current review incomplete
      H51-C2B4754741056D8F2B6F2522dosing.json
      /records/99/coverage_status
      Historical; current review incomplete
      H51-A51B6064850D3581898D7B44dosing.json
      /records/99/package_insert/query_name
      Historical; current review incomplete
      H51-C3D85C7E626CCB84BFE81892dosing.json
      /records/99/package_insert/preferred_setid
      Historical; current review incomplete
      H51-8B7564BF3E4DBC5CD482397Bdosing.json
      /records/99/package_insert/product_and_route_must_match
      Historical; current review incomplete
      H51-37D4AEE708983DD57AD53C9Fdosing.json
      /records/99/package_insert/live_current_label_enabled
      Historical; current review incomplete
      H51-A9CC51739FAD6810AB9138D1dosing.json
      /records/99/package_insert/source_priority
      Historical; current review incomplete
      H51-E3C5237ECA1C06BE4C93BF82dosing.json
      /records/99/package_insert/direct_official_label_access_enabled
      Historical; current review incomplete
      H51-9A335BFA2E4D030E8B3E6252dosing.json
      /records/99/package_insert/outbound_server_request_required
      Historical; current review incomplete
      H51-4351EEE57EFB9753630E3A02dosing.json
      /records/99/package_insert/local_summary_status
      Historical; current review incomplete
      H51-6C1FF40F6C90806719678D69dosing.json
      /records/99/renal/classification
      Historical; current review incomplete
      H51-81CD4E5E2EA669D772B30BE7dosing.json
      /records/99/renal/summary
      Historical; current review incomplete
      H51-9869F79DFC8695E1C6A38902dosing.json
      /records/99/renal/method_note
      Historical; current review incomplete
      H51-B2C2B64467BC1B1C4D8DC40Edosing.json
      /records/99/clinical_review/locally_normalized
      Historical; current review incomplete
      H51-6801710F762D82ADD41A10A7dosing.json
      /records/99/clinical_review/reviewed
      Historical; current review incomplete
      H51-A6F30A2A54E817CA9916DAA0dosing.json
      /records/99/clinical_review/status
      Historical; current review incomplete
      H51-C5B46CD3D35E29A371382525dosing.json
      /records/99/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-571E0F58A1B1DCAF422F5A51dosing.json
      /records/99/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-7BD664A93B8103D1F6F83BF2dosing.json
      /records/99/clinical_release_verification/level
      Historical; current review incomplete
      H51-0229CA8301DB71BEC3630A8Cdosing.json
      /records/99/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-8306B9FEBE353863B328C8D9dosing.json
      /records/99/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-E8B4A9498551B295E81D1F26dosing.json
      /records/99/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-047CAD9884F7C8AF16148139dosing.json
      /records/99/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-7C89ACDEEAF3C772033E2510dosing.json
      /records/99/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-FCB7B812A32E18CD1A328EFCdosing.json
      /records/99/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-804FF51CEB5F6124594861E9dosing.json
      /records/99/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-8B574E701394E53585967DA1dosing.json
      /records/99/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-249F87A34A0A6AC1DC88865Ddosing.json
      /records/99/clinical_release_verification/note
      Historical; current review incomplete
      H51-346ABA31B06C02E11CDD63DCdosing.json
      /records/99/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-2EE01C5AB9C2C1EE43D83D4Ffirst-look-v5.1.json
      /records/99/id
      Historical; current review incomplete
      H51-A8FDE770B5C296740537AD30first-look-v5.1.json
      /records/99/generic_name
      Historical; current review incomplete
      H51-A8ECC6FA82D48BD47DB0E29Dfirst-look-v5.1.json
      /records/99/class
      Historical; current review incomplete
      H51-B46B672726F1841296052F43first-look-v5.1.json
      /records/99/subclass
      Historical; current review incomplete
      H51-0987498FBDE5401236DB5422first-look-v5.1.json
      /records/99/primary_uses/0
      Historical; current review incomplete
      H51-692F1105658DD7B7B604420Bfirst-look-v5.1.json
      /records/99/mechanism
      Historical; current review incomplete
      H51-53DBE7894683CF2F8DD3698Ffirst-look-v5.1.json
      /records/99/mechanism_level
      Historical; current review incomplete
      H51-0253308F382286C396FE2B63first-look-v5.1.json
      /records/99/basic_dosing_orientation
      Historical; current review incomplete
      H51-71B745686BD46236DE039E26first-look-v5.1.json
      /records/99/administration_orientation
      Historical; current review incomplete
      H51-323902BA86DAC748181F9C46first-look-v5.1.json
      /records/99/renal_and_population_orientation
      Historical; current review incomplete
      H51-FC03A7D379F7EB50D3953221first-look-v5.1.json
      /records/99/key_safety_orientation/0
      Historical; current review incomplete
      H51-5404814743B7B927F1F4939Ffirst-look-v5.1.json
      /records/99/coverage_path
      Historical; current review incomplete
      H51-6F9A3370EBA54BDF1E352598first-look-v5.1.json
      /records/99/coverage_path_label
      Historical; current review incomplete
      H51-8A3909287C043D11AC8FA7BAfirst-look-v5.1.json
      /records/99/official_label_url
      Historical; current review incomplete
      H51-4AF7FA8FB53EB9EAE2C1D7AEfirst-look-v5.1.json
      /records/99/legacy_title
      Historical; current review incomplete
      H51-A2A17407B44895ED5AEFCB21first-look-v5.1.json
      /records/99/review_note
      Historical; current review incomplete
      H51-595BCA0B9D3FAE1B7B101099first-look-v5.1.json
      /records/99/search_text
      Historical; current review incomplete
      H51-32D2247EAE92B058A1F4EEB5first-look-v5.1.json
      /records/99/official_search_url
      Historical; current review incomplete
      H51-C28B4D3217F22DBCC1558071first-look-v5.1.json
      /records/99/official_access_mode
      Historical; current review incomplete
      H51-E9CEEEB46DF8A24A3997D82Dfirst-look-v5.1.json
      /records/99/official_access_url
      Historical; current review incomplete
      H51-4354D765121FCD3F0770CCE5first-look-v5.1.json
      /records/99/official_search_query
      Historical; current review incomplete
      H51-9E07B2C9A180B47A2FA15AF1first-look-v5.1.json
      /records/99/official_access_reason
      Historical; current review incomplete
      H51-6512C0144389C4F6D9108768preparation-assessments-v3.8.json
      /99/id
      Historical; current review incomplete
      H51-0D081706FBBC50033071F167preparation-assessments-v3.8.json
      /99/name
      Historical; current review incomplete
      H51-396F225E20D4CB2A0100F851preparation-assessments-v3.8.json
      /99/brands
      Historical; current review incomplete
      H51-0F449E24AD1EF295BA9F2FDApreparation-assessments-v3.8.json
      /99/therapeutic_class
      Historical; current review incomplete
      H51-CC630AFDC7A02A3643CFE227preparation-assessments-v3.8.json
      /99/review_version
      Historical; current review incomplete
      H51-55707D91E279A1E339CA5FFBpreparation-assessments-v3.8.json
      /99/review_date
      Historical; current review incomplete
      H51-4627CD86BCEAE61498942073preparation-assessments-v3.8.json
      /99/release_status
      Historical; current review incomplete
      H51-5F57E16FAD06563D8272A62Cpreparation-assessments-v3.8.json
      /99/market_status/status
      Historical; current review incomplete
      H51-8F1A3572EBB3C29ECE7F2FCCpreparation-assessments-v3.8.json
      /99/market_status/basis
      Historical; current review incomplete
      H51-DA97BEA7BDB95140A64B221Epreparation-assessments-v3.8.json
      /99/ten_point_assessment/exact_formulation
      Historical; current review incomplete
      H51-CC15FDE770FC8FC7777A0F60preparation-assessments-v3.8.json
      /99/ten_point_assessment/reconstitution_concentration
      Historical; current review incomplete
      H51-5C3233EAB9BBD02F5F83AC8Epreparation-assessments-v3.8.json
      /99/ten_point_assessment/maximum_or_recommended_final_concentration
      Historical; current review incomplete
      H51-CE63F44A3787F051C2853146preparation-assessments-v3.8.json
      /99/ten_point_assessment/appropriate_standardized_containers
      Historical; current review incomplete
      H51-410C90D52F03739A18C16270preparation-assessments-v3.8.json
      /99/ten_point_assessment/adult_dosing_range
      Historical; current review incomplete
      H51-4A607EB7E55E34E16FB2456Cpreparation-assessments-v3.8.json
      /99/ten_point_assessment/pediatric_dosing_range
      Historical; current review incomplete
      H51-8C93630E0B898D637A174D32preparation-assessments-v3.8.json
      /99/ten_point_assessment/neonatal_dosing_range
      Historical; current review incomplete
      H51-4AD3517C6616FE7CCF6CCCB5preparation-assessments-v3.8.json
      /99/ten_point_assessment/infusion_time
      Historical; current review incomplete
      H51-35C380BEE6AA48542216229Fpreparation-assessments-v3.8.json
      /99/ten_point_assessment/fluid_restriction_alternatives
      Historical; current review incomplete
      H51-56BA13F0B7EDED1FA3DDFABEpreparation-assessments-v3.8.json
      /99/ten_point_assessment/current_manufacturer_labeling/setid
      Historical; current review incomplete
      H51-EAB91DB7A75C66BC6D09C471preparation-assessments-v3.8.json
      /99/ten_point_assessment/current_manufacturer_labeling/title
      Historical; current review incomplete
      H51-D2C199BC44015B7C9BD154F8preparation-assessments-v3.8.json
      /99/ten_point_assessment/current_manufacturer_labeling/published_date
      Historical; current review incomplete
      H51-A0DBB4DFE1F4ECBD8DD7FCAApreparation-assessments-v3.8.json
      /99/ten_point_assessment/current_manufacturer_labeling/manufacturer
      Historical; current review incomplete
      H51-EAF4D13547B1F5D188725D62preparation-assessments-v3.8.json
      /99/ten_point_assessment/current_manufacturer_labeling/match_confidence
      Historical; current review incomplete
      H51-EAEC8CF4E3EACE7711F57AACpreparation-assessments-v3.8.json
      /99/ten_point_assessment/current_manufacturer_labeling/url
      Historical; current review incomplete
      H51-69F72AB4BAB5F4CE43E06719preparation-assessments-v3.8.json
      /99/field_provenance/exact_formulation/primary
      Historical; current review incomplete
      H51-F8DEE6FCC2D7E5F7432572CEpreparation-assessments-v3.8.json
      /99/field_provenance/reconstitution_concentration/primary
      Historical; current review incomplete
      H51-296824FB8260CEF047CB8369preparation-assessments-v3.8.json
      /99/field_provenance/maximum_or_recommended_final_concentration/primary
      Historical; current review incomplete
      H51-D4D80E7FC3EA07E83F2A8210preparation-assessments-v3.8.json
      /99/field_provenance/appropriate_standardized_containers/primary
      Historical; current review incomplete
      H51-316D95A65776FB7BB36C5335preparation-assessments-v3.8.json
      /99/field_provenance/adult_dosing_range/primary
      Historical; current review incomplete
      H51-42664667A20B5C3E96DDDA2Fpreparation-assessments-v3.8.json
      /99/field_provenance/pediatric_dosing_range/primary
      Historical; current review incomplete
      H51-189D47E44776C97A8EB04983preparation-assessments-v3.8.json
      /99/field_provenance/neonatal_dosing_range/primary
      Historical; current review incomplete
      H51-45864F6CF1D82BC60A8773BEpreparation-assessments-v3.8.json
      /99/field_provenance/infusion_time/primary
      Historical; current review incomplete
      H51-5E38010A48A5092C2BFCA6BCpreparation-assessments-v3.8.json
      /99/field_provenance/fluid_restriction_alternatives/primary
      Historical; current review incomplete
      H51-D97222512202E5DEB7A06999preparation-assessments-v3.8.json
      /99/field_provenance/current_manufacturer_labeling/primary
      Historical; current review incomplete
      H51-B8C1358511929BBD2571D090preparation-assessments-v3.8.json
      /99/population_applicability/adult/applicability
      Historical; current review incomplete
      H51-141C774CE4832650DB103952preparation-assessments-v3.8.json
      /99/population_applicability/adult/guide_generation_allowed
      Historical; current review incomplete
      H51-BC91E747BB2AFB58A5A8716Apreparation-assessments-v3.8.json
      /99/population_applicability/pediatric/applicability
      Historical; current review incomplete
      H51-0DD4FBDD8FF54BDDBA206A48preparation-assessments-v3.8.json
      /99/population_applicability/pediatric/guide_generation_allowed
      Historical; current review incomplete
      H51-DE1609F48512C4F41D70BBABpreparation-assessments-v3.8.json
      /99/population_applicability/neonatal/applicability
      Historical; current review incomplete
      H51-B9A55F89EC082ECFF3B705E3preparation-assessments-v3.8.json
      /99/population_applicability/neonatal/guide_generation_allowed
      Historical; current review incomplete
      H51-7B0C84B3938F20F973BF7FD5preparation-assessments-v3.8.json
      /99/route_presence/structured_dilution
      Historical; current review incomplete
      H51-7B18B643CEF355A7AAF9BA6Cpreparation-assessments-v3.8.json
      /99/route_presence/iv_push
      Historical; current review incomplete
      H51-BDF6BFAC5A9100E11B8638CCpreparation-assessments-v3.8.json
      /99/route_presence/continuous_infusion
      Historical; current review incomplete
      H51-B1E63EC8D2582985534461DFpreparation-assessments-v3.8.json
      /99/route_presence/pediatric_source
      Historical; current review incomplete
      H51-54377031C196427143ECE250preparation-assessments-v3.8.json
      /99/route_presence/neonatal_source
      Historical; current review incomplete
      H51-94C78715ABEC269AD708612Epreparation-assessments-v3.8.json
      /99/legacy_reference/status
      Historical; current review incomplete
      H51-5656B036F86F26351572E935preparation-assessments-v3.8.json
      /99/label_resolution/status
      Historical; current review incomplete
      H51-58FF25B98DE8B2211DF8833Fpreparation-assessments-v3.8.json
      /99/source_files/0
      Historical; current review incomplete
      H51-9A11481617C2C708F1E780BCpreparation-assessments-v3.8.json
      /99/source_files/1
      Historical; current review incomplete
      H51-4A79D7F8F00FF3060AE1E7DEpreparation-assessments-v3.8.json
      /99/source_files/2
      Historical; current review incomplete
      H51-CA059C8203FD7A5C1559C666preparation-assessments-v3.8.json
      /99/source_files/3
      Historical; current review incomplete
      H51-AD9788269316D8B0947B2D54preparation-assessments-v3.8.json
      /99/clinical_release_note
      Historical; current review incomplete